Roy, D. G. http://orcid.org/0000-0002-6044-0118
Geoffroy, K. http://orcid.org/0000-0002-6093-349X
Marguerie, M.
Khan, S. T.
Martin, N. T.
Kmiecik, J.
Bobbala, D.
Aitken, A. S.
de Souza, C. T.
Stephenson, K. B.
Lichty, B. D.
Auer, R. C.
Stojdl, D. F.
Bell, J. C. http://orcid.org/0000-0002-9083-357X
Bourgeois-Daigneault, M.-C. http://orcid.org/0000-0002-9091-2235
Article History
Received: 23 July 2019
Accepted: 7 April 2021
First Online: 11 May 2021
Competing interests
: J.C.B., B.D.L. and D.F.S. have equity interest in Turnstone Biologics, which develops MRB as an OV platform and M.C.B.D. and J.C.B. are inventors on a patent describing the use of OVs as adjuvants for anticancer vaccination. All other authors declare no competing interests. All data associated with this study are available in the main text or the InternalRef removed.